Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New hope for kids with brain tumors: drug that crosses the Blood-Brain barrier enters trials

NCT ID NCT04923126

First seen Feb 04, 2026 · Last updated May 23, 2026 · Updated 15 times

Summary

This study tests a drug called mirdametinib in children, adolescents, and young adults with low-grade glioma, a type of brain tumor. The drug is designed to reach the brain and block signals that help tumors grow. The goal is to find the best dose, check safety, and see if it can shrink or stabilize tumors. About 132 participants will take the drug twice daily.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LOW GRADE GLIOMA are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • St. Jude Children's Research Hospital

    RECRUITING

    Memphis, Tennessee, 38105, United States

    Contact

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.